NCT02688647: A reported trial by Kadmon Corporation, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02688647 |
|---|---|
| Title | A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 26, 2016 |
| Completion date | April 13, 2021 |
| Required reporting date | April 13, 2022, midnight |
| Actual reporting date | April 13, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |